Brief: China Medical System Says Unit Entered Into Exclusive Commercialization Agreement
Dec 2 (Reuters) - China Medical System 0867.HK :
* UNIT ENTERED INTO EXCLUSIVE COMMERCIALIZATION AGREEMENT
WITH
ATOM THERAPEUTICS
* DEAL FOR COMMERCIALIZATION OF CLASS 1 INNOVATIVE DRUG
ABP-671
FOR TREATMENT OF GOUT & HYPERURICEMIA
Further company coverage: 0867.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Medical System Holdings
See all newsBrief: China Medical System Says CMS-D001 Granted Drug Clinical Trial Approval Notice By NMPA
Brief: China Medical System Holdings Says Dermavon Receives NMPA Approval For Lumirix NDA For Atopic Dermatitis
China Medical System climbs most in six weeks on higher profit, dividend
China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
AI shortens drug discovery to around 1 year in China, Insilico CEO says